Topics

Managing partner at Numerof & Associates.

Articles

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Looking at the essential value of well-managed supply chains

HDMA seeks to encourage more outreach to business partners and government

Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay

A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets

Fees paid to FDA by small generic manufacturers are financially 'unfair'

The pharma industry needs to go farther in adapting to new marketplace realities